These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27269948)

  • 1. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
    J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
    Muranen TA; Greco D; Blomqvist C; Aittomäki K; Khan S; Hogervorst F; Verhoef S; Pharoah PDP; Dunning AM; Shah M; Luben R; Bojesen SE; Nordestgaard BG; Schoemaker M; Swerdlow A; García-Closas M; Figueroa J; Dörk T; Bogdanova NV; Hall P; Li J; Khusnutdinova E; Bermisheva M; Kristensen V; Borresen-Dale AL; ; Peto J; Dos Santos Silva I; Couch FJ; Olson JE; Hillemans P; Park-Simon TW; Brauch H; Hamann U; Burwinkel B; Marme F; Meindl A; Schmutzler RK; Cox A; Cross SS; Sawyer EJ; Tomlinson I; Lambrechts D; Moisse M; Lindblom A; Margolin S; Hollestelle A; Martens JWM; Fasching PA; Beckmann MW; Andrulis IL; Knight JA; ; Anton-Culver H; Ziogas A; Giles GG; Milne RL; Brenner H; Arndt V; Mannermaa A; Kosma VM; Chang-Claude J; Rudolph A; Devilee P; Seynaeve C; Hopper JL; Southey MC; John EM; Whittemore AS; Bolla MK; Wang Q; Michailidou K; Dennis J; Easton DF; Schmidt MK; Nevanlinna H
    Genet Med; 2017 May; 19(5):599-603. PubMed ID: 27711073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls.
    Yang Y; Zhang F; Wang Y; Liu SC
    Asian Pac J Cancer Prev; 2012; 13(7):3501-5. PubMed ID: 22994785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients.
    Wendt C; Muranen TA; Mielikäinen L; Thutkawkorapin J; Blomqvist C; Jiao X; Ehrencrona H; Tham E; Arver B; Melin B; Kuchinskaya E; Stenmark Askmalm M; Paulsson-Karlsson Y; Einbeigi Z; von Wachenfeldt Väppling A; Kalso E; Tasmuth T; Kallioniemi A; Aittomäki K; Nevanlinna H; Borg Å; Lindblom A
    Sci Rep; 2021 Jul; 11(1):14763. PubMed ID: 34285278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer.
    Huijts PE; Hollestelle A; Balliu B; Houwing-Duistermaat JJ; Meijers CM; Blom JC; Ozturk B; Krol-Warmerdam EM; Wijnen J; Berns EM; Martens JW; Seynaeve C; Kiemeney LA; van der Heijden HF; Tollenaar RA; Devilee P; van Asperen CJ
    Eur J Hum Genet; 2014 Jan; 22(1):46-51. PubMed ID: 23652375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between CHEK2*1100delC and Breast Cancer: A Systematic Review and Meta-Analysis.
    Liang M; Zhang Y; Sun C; Rizeq FK; Min M; Shi T; Sun Y
    Mol Diagn Ther; 2018 Aug; 22(4):397-407. PubMed ID: 29909568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
    Morra A; Schreurs MAC; Andrulis IL; Anton-Culver H; Augustinsson A; Beckmann MW; Behrens S; Bojesen SE; Bolla MK; Brauch H; Broeks A; Buys SS; Camp NJ; Castelao JE; Cessna MH; Chang-Claude J; Chung WK; ; Colonna SV; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Dennis J; Devilee P; Dörk T; Dunning AM; Dwek M; Easton DF; Eccles DM; Eriksson M; Evans DG; Fasching PA; Fehm TN; Figueroa JD; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Genkinger J; Grassmann F; Gündert M; Hahnen E; Haiman CA; Hamann U; Harrington PA; Hartikainen JM; Hoppe R; Hopper JL; Houlston RS; Howell A; ; ; Jakubowska A; Janni W; Jernström H; John EM; Johnson N; Jones ME; Kristensen VN; Kurian AW; Lambrechts D; Le Marchand L; Lindblom A; Lubiński J; Lux MP; Mannermaa A; Mavroudis D; Mulligan AM; Muranen TA; Nevanlinna H; Nevelsteen I; Neven P; Newman WG; Obi N; Offit K; Olshan AF; Park-Simon TW; Patel AV; Peterlongo P; Phillips KA; Plaseska-Karanfilska D; Polley EC; Presneau N; Pylkäs K; Rack B; Radice P; Rashid MU; Rhenius V; Robson M; Romero A; Saloustros E; Sawyer EJ; Schmutzler RK; Schuetze S; Scott C; Shah M; Smichkoska S; Southey MC; Tapper WJ; Teras LR; Tollenaar RAEM; Tomczyk K; Tomlinson I; Troester MA; Vachon CM; van Veen EM; Wang Q; Wendt C; Wildiers H; Winqvist R; Ziogas A; Hall P; Pharoah PDP; Adank MA; Hollestelle A; Schmidt MK; Hooning MJ
    Cancer Med; 2023 Aug; 12(15):16142-16162. PubMed ID: 37401034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.
    CHEK2 Breast Cancer Case-Control Consortium
    Am J Hum Genet; 2004 Jun; 74(6):1175-82. PubMed ID: 15122511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.
    Muranen TA; Blomqvist C; Dörk T; Jakubowska A; Heikkilä P; Fagerholm R; Greco D; Aittomäki K; Bojesen SE; Shah M; Dunning AM; Rhenius V; Hall P; Czene K; Brand JS; Darabi H; Chang-Claude J; Rudolph A; Nordestgaard BG; Couch FJ; Hart SN; Figueroa J; García-Closas M; Fasching PA; Beckmann MW; Li J; Liu J; Andrulis IL; Winqvist R; Pylkäs K; Mannermaa A; Kataja V; Lindblom A; Margolin S; Lubinski J; Dubrowinskaja N; Bolla MK; Dennis J; Michailidou K; Wang Q; Easton DF; Pharoah PD; Schmidt MK; Nevanlinna H
    Breast Cancer Res; 2016 Oct; 18(1):98. PubMed ID: 27716369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
    Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D
    Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of breast cancer associated with CHEK2*1100delC.
    Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
    J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between the CHEK2*1100delC germ line mutation and estrogen receptor status.
    de Bock GH; Mourits MJ; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    Int J Gynecol Cancer; 2006; 16 Suppl 2():552-5. PubMed ID: 17010071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
    Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
    BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CHEK2-mutation in Dutch breast cancer families: expanding genetic testing for breast cancer].
    Adank MA; Hes FJ; van Zelst-Stams WA; van den Tol MP; Seynaeve C; Oosterwijk JC
    Ned Tijdschr Geneeskd; 2015; 159():A8910. PubMed ID: 26332814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
    Weischer M; Nordestgaard BG; Pharoah P; Bolla MK; Nevanlinna H; Van't Veer LJ; Garcia-Closas M; Hopper JL; Hall P; Andrulis IL; Devilee P; Fasching PA; Anton-Culver H; Lambrechts D; Hooning M; Cox A; Giles GG; Burwinkel B; Lindblom A; Couch FJ; Mannermaa A; Grenaker Alnæs G; John EM; Dörk T; Flyger H; Dunning AM; Wang Q; Muranen TA; van Hien R; Figueroa J; Southey MC; Czene K; Knight JA; Tollenaar RA; Beckmann MW; Ziogas A; Christiaens MR; Collée JM; Reed MW; Severi G; Marme F; Margolin S; Olson JE; Kosma VM; Kristensen VN; Miron A; Bogdanova N; Shah M; Blomqvist C; Broeks A; Sherman M; Phillips KA; Li J; Liu J; Glendon G; Seynaeve C; Ekici AB; Leunen K; Kriege M; Cross SS; Baglietto L; Sohn C; Wang X; Kataja V; Børresen-Dale AL; Meyer A; Easton DF; Schmidt MK; Bojesen SE
    J Clin Oncol; 2012 Dec; 30(35):4308-16. PubMed ID: 23109706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls.
    Fletcher O; Johnson N; Dos Santos Silva I; Kilpivaara O; Aittomäki K; Blomqvist C; Nevanlinna H; Wasielewski M; Meijers-Heijerboer H; Broeks A; Schmidt MK; Van't Veer LJ; Bremer M; Dörk T; Chekmariova EV; Sokolenko AP; Imyanitov EN; Hamann U; Rashid MU; Brauch H; Justenhoven C; Ashworth A; Peto J
    Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):230-4. PubMed ID: 19124502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.